Glenya Uses

DRUGS and MEDICATIONS
Gilenya


GENERIC NAME(S): FINGOLIMOD HCL

Alert The FDA is investigating a possible link between Gilenya and a case of a rare brain infection in one patient.

Uses

This medication is used to treat a certain type of multiple sclerosis (relapsing-remitting multiple sclerosis-MS). It is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord. It helps decrease the number of episodes of worsening and may prevent or delay disability.

How to use Gilenya

Read the Medication Guide provided by your pharmacist before you start taking fingolimod and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Before starting fingolimod, your doctor will do medical/laboratory tests (such as complete blood count,blood pressure, EKG, pulse) to monitor for side effects. Take this medication by mouth with or without food as directed by your doctor, usually once a day. You will be monitored for at least 6 hours after the first dose to make sure your heartbeat does not go too slow. A very slow heartbeat increases the risk for a serious heartrhythm problem (QT prolongation in the EKG). Tell your doctor if you have low levels of magnesium/potassium in the blood, personal or family history of QT prolongation in the EKG, family history of sudden cardiac death, orheart failure. Also tell your doctor if you are taking other drugs that can slow down your heartbeat or affect heart rhythm (such as causing QT prolongation in the EKG). 

See also Drug Interactions section.

If you temporarily stop taking fingolimod after starting treatment, you may need to be monitored again for at least 6 hours after you restart this medication. Ask your doctor for details.

Do not increase your dose or take this medication more often than prescribed. Your condition will not improve any faster, and the risk of serious side effects may be increased.

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.

Tell your doctor if your condition does not improve or if it worsens.


What conditions does Gilenya treat?

Smoking Marijuana for 50 Years

N.Y. / REGION

Smoking Marijuana for 50 Years, and Turning Out Just Fine

APRIL 12, 2015

Catherine Hiller, author of "Just Say Yes: A Marijuana Memoir," at Prospect Park in Brooklyn, where she believes she first smoked marijuana in the 1960s. 

CreditDavid Gonzalez/The New York Times

As much as Catherine Hiller refuses to admit it, marijuana is a gateway drug. Seriously, after smoking more or less every day for the past 50 years, there had to be some consequences. Yet, she did not go to jail after a random police stop. She did not end up strung out on heroin, sprawled in an alley. She didn’t even binge-munch herself into obesity.

Her daily puffs led her to write a book, “Just Say Yes: A Marijuana Memoir.”

Just in case people approached her story waiting for the Lifetime movie moment of regret and picking up the pieces of a broken life, she started her book in the present day, flashing back, if you will, to the rest of her life. As a writer — she has published novels and short stories — the approach was an entertaining challenge. As a wife, daughter of an activist and proud mother of three young men, she wanted to show that her life turned out nicely.

“I wanted to show people that smoking marijuana did not make me hit rock bottom,” Ms. Hiller, 68, said. “My story is the story of so many people who use each day. And so what? What’s the issue? What will it lead to?”

Well, in the case of minority youths, it could lead to jail time and a criminal record, something Ms. Hiller feels is unjust. 

Recently, a young man smoking a joint in a Bronx building was mortally injured when he fell off a roof while running from police officers who entered the lobby after reports that marijuana was being used in public view. 

On the other hand, she and other marijuana advocates wonder about the criminal charges attached to using when banks, like HSBC, laundered drug money but got off with a fine and no criminal indictments.
She has experienced the disparities of race and class when it comes to how law enforcement looks at smokers. In her book, she recounts how after she and her first husband lit up in their car, a policeman flashed a spotlight on them, told them to put out the joint and then waved them off. 

After an essay adapted from her book was published in The New York Times, someone accused her of living in a cocoon of white privilege.
“Maybe I won’t get stopped,” she said. “But I wrote this not because of my privilege, but because I think it’s absurd that anyone would get stopped for this. Whatever I can do to legalize it, I will.”
She had taken a dim view of marijuana when she was a teenager living in Park Slope, Brooklyn, in 1963 and learned that a girlfriend got high at a party. 

Like someone who took her cue from the propaganda film “Reefer Madness,” she thought her friend would descend into a dissolute life of jazz and juke joints.

But somehow, Ms. Hiller changed her mind not too long afterward...

People might think she is some sort of party girl, but to hear her tell it, she is somewhat sedate. Ms. Hiller has had the same dealer for 35 years, watching as his regulars have gotten older and grayer. And there are many things she will not do while high, including driving and attending gatherings where she does not know many people.

Ms. Hiller is looking forward to her book tour, which will take her to at least one dispensary on the West Coast. Not that she justifies her use by claiming medical need.

“I don’t need it to relieve cramps,” she said. “I just like the feeling.”

Some of her neighbors in the New York suburb where she now lives do, too, she said. It amuses her to discover “secret smokers,” even if the whole idea of secrecy is, to her, a holdover from an alarmist and judgmental era. 

She hopes her book and campaign — where she invites readers to share their stories on her website,marijuanamemoir.com — will lead to a change of opinion and laws.



A version of this article appears in print on April 13, 2015, on page A16 of the New York edition with the headline: Smoking Marijuana for 50 Years, and Turning Out Just Fine.


http://www.nytimes.com/2015/04/13/nyregion/after-50-years-of-smoking-marijuana-her-life-turned-out-nicely.html

Tilray cultivates medical cannabis on Vancouver Island

About Tilray

At Tilray, we're dedicated to cultivating and delivering the benefits of medical cannabis safely and reliably. Our team of PhDs, botanists and master horticulturists are industry leaders in medical cannabis research and related agricultural sciences. At Tilray, we’re constantly looking for ways to make your experience more efficient and convenient.


Here are some of the ways you benefit with us:

Latest Strains

At Tilray, we’re constantly adding to our collection of strains. Registered Tilray patients who opt in to receive e-mail newsletters will be notified as soon as new strains are available. They will be the first to know about new strains and their unique characteristics.


Expedited Shipping

Orders placed by 3:30 PM ET/12:30 PM PT are generally shipped on the same business day. In most cases, orders will be delivered the following business day across Canada, exceptions being rural areas and orders placed over the weekend or on national holidays.


Around-the-Clock Support

Have questions or concerns? Tilray is proud to offer its patients support 24 hours a day, 7 days a week. Simply dial 1-844-TILRAY1 (845-7291) or email us at tilray@tilray.ca. Whatever you need, we’re here to help. Because at Tilray, we’re committed to meeting patient needs, and exceeding patient expectations.


What are the Marihuana for Medical Purposes Regulations (MMPR)?

The new Marihuana for Medical Purposes Regulations (MMPR) replace the Marihuana Medical Access Regulations (MMAR). As of April 1, 2014, individuals may only access cannabis for medical purposes from licensed producers approved by Health Canada. Learn more.

A Federal Court injunction has allowed MMAR patients to continue growing their own cannabis or have a designated producer continue to grow their cannabis, at least until the court case has been resolved.

Is medical cannabis safe?

When consumed responsibly, medical cannabis can be an effective and safe natural remedy for some patients. However, dried medical cannabis is not for everyone. You may have a physical or psychological condition that increases the risk of adverse effects. Tilray recommends that you consult with your health care practitioner before consuming and maintain regular checkups throughout your treatment. For studies and stories that focus on the medical aspects of medical cannabis, visit Tilray Updates and Science.

Tilray raises the bar for quality and responsible production. We rigorously test our products to ensure they are free of pesticides and other contaminants. Every step of production, from growing to packaging to distribution, is strictly controlled for freshness and quality you can trust. You can learn more on our About Us page.


Who can be a Tilray client?

As a Licensed Producer under Health Canada guidelines, Tilray accepts registration from any individual who ordinarily resides in Canada and provides the appropriate medical documents signed by a health care practitioner.

Individuals must provide the following two documents, and upon approval by Tilray will receive a patient number to place orders online or via phone:




https://www.tilray.ca/en/Home/HowItWorks

Gilenya ( FINGOLIMOD HCL)

DRUGS and MEDICATIONS 

Gilenya

GENERIC NAME(S): FINGOLIMOD HCL  

Alert The FDA is investigating a possible link between Gilenya and a case of a rare brain infection in one patient.


Uses

This medication is used to treat a certain type of multiple sclerosis (relapsing-remitting multiple sclerosis-MS). It is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord. It helps decrease the number of episodes of worsening and may prevent or delay disability.

How to use Gilenya

Read the Medication Guide provided by your pharmacist before you start taking fingolimod and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Before starting fingolimod, your doctor will do medical/laboratory tests (such as complete blood count,blood pressure, EKG, pulse) to monitor for side effects. 

Take this medication by mouth with or without food as directed by your doctor, usually once a day. You will be monitored for at least 6 hours after the first dose to make sure your heartbeat does not go too slow. A very slow heartbeat increases the risk for a serious heartrhythm problem (QT prolongation in the EKG). 

Tell your doctor if you have low levels of magnesium/potassium in the blood, personal or family history of QT prolongation in the EKG, family history of sudden cardiac death, or heart failure. Also tell your doctor if you are taking other drugs that can slow down your heartbeat or affect heart rhythm (such as causing QT prolongation in the EKG). See also Drug Interactions section.

If you temporarily stop taking fingolimod after starting treatment, you may need to be monitored again for at least 6 hours after you restart this medication. Ask your doctor for details.

Do not increase your dose or take this medication more often than prescribed. Your condition will not improve any faster, and the risk of serious side effects may be increased.

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.

Tell your doctor if your condition does not improve or if it worsens.

How it works:

Gilenya prevents the T-cells, the immune cells, from getting out of the lymph nodes. I tell my patients it's like the "roach motel" model of immunity. They can check in, but they can't check out.

The T-cells can't get out of lymph nodes and into the blood. If they can't get into the blood, they can't get into the nervous system.

Gilenya also may protect the brain.

Side Affects:

Gilenya has known side effects of liver enzyme elevations [potentially causing liver disease], lowering of the white blood cell count [reducing infection-fighting ability], and slowing the heart rate.

A year or so after it came out, there were sudden deaths. These were people who had pre-existing heart problems or were on heartmedication. So they had to change the labeling. Now, if someone has certain types of heart conditions or is on certain types of heart medication, Gilenya is not prescribed.

What conditions does Gilenya treat?

Relaxing and Remitting types of m.s.



Source:
http://www.webmd.com/drugs/2/drug-154676/gilenya+oral/details

Tilray Study with UBC By Tilray News Editor 11/13/2014

 By Tilray News Editor 11/13/2014

We’re pleased to announce a partnership with the University of British Columbia to conduct the country’s first clinical trial evaluating the therapeutic benefits of medical cannabis as treatment for post-traumatic stress disorder (PTSD).

Pending regulatory approvals, the study is poised to be one of the first in the world to run a large-scale clinical trial examining medical cannabis as a treatment for a mental health disorder.

Study participants will include 40 men and women who meet clinical criteria for PTSD due to trauma experienced during military service, as a first responder, or as the result of sexual assault.

The trial is expected to launch in early summer 2015, pending necessary regulatory approvals, and is scheduled to conclude in late 2016.

Source: https://www.tilray.ca/

Optic neuritis trials: encouraging results

MS Society UK @mssocietyuk · Apr 17


Positive results from early trials into nerve cell protection &myelin repair in optic neuritis http://bit.ly/1HzB6ha

Optic neuritis trials: encouraging results announced

Published date: 16 Apr 2015 at 5:56PM

Positive results from two separate phase two clinical trials in optic neuritis will be announced at the American Academy of Neurology’s 67th Annual Meeting in Washington next week.

The two drugs, known as phenytoin and anti-LINGO-1, have been shown to have a positive effect in optic neuritis, a condition that around half of people with MS experience. 

Optic neuritis is caused by inflammation and damage to the nerves carrying information between the eye and the brain, and can result in sudden blurred vision and partial or even total blindness.

Phenytoin – protecting nerve cells

The drug phenytoin is commonly taken to prevent epileptic seizures, but may also protect nerves from damage according to results announced from a new phase two clinical trial.

Dr Raj Kapoor led the trial at University College London (UCL), which recruited 86 people who were experiencing early symptoms of acute optic neuritis. Participants were given either phenytoin or a placebo drug for a three month period. The team then assessed whether the drug could help to protect the retina (the light sensitive nerve layer at the back of the eye) from damage by measuring the thickness of the retinal nerve fibre layer, once at the beginning of the study, and again six months later.

Findings

The team found that:

• The group who took phenytoin had 30% less damage to the retinal nerve fibre layer compared to those who received the placebo
• The volume of the macula, the most light-sensitive part of the retina, was 34% higher in those who took phenytoin than those who received the placebo

Most people recover vision from their first episode of optic neuritis and in this trial there weren’t any significant differences found in the long term visual outcomes between the two groups.

Promising results

Dr Raj Kapoor, MD, at the University College London Hospital, said: “These are promising results and if our findings are confirmed by larger studies, could lead to a new treatment that protects nerves from the damage caused both in optic neuritis and throughout the central nervous system in MS.”

The study was co-funded by the MS Society, the National Multiple Sclerosis Society, an unrestricted grant from Novartis, the National Institute for Health Research Clinical Research Network and University College London Hospitals Biomedical Research Center.

Anti-LINGO-1 – repairing myelin

The RENEW trial tested the drug anti-LINGO-1, which is under development by Biogen and has been shown to promote myelin repair in an animal model of MS.

The trial involved 82 participants with a first episode of acute optic neuritis, who were given anti-LINGO-1 or a placebo infusion. Researchers measured the time it took for nerve impulses to travel from the retina to the brain and found that in the group that took anti-LINGO-1, there was an improvement in this signaling time, suggesting that remyelination is happening in these people.

Encouraging news

Dr Emma Gray, Head of Biomedical Research at the MS Society said:

“This is the first indication that a drug could promote remyelination in people, which is hugely encouraging news. People with MS are in desperate need of treatments that slow or halt the progression the condition, and repairing myelin is a promising way to do this.

"These trial results in optic neuritis represent another positive step towards developing myelin repair treatments for people with MS.”

Next steps

These announcements are the first time the new results have been shown to the research community, and they will now need to be published in a peer-reviewed journal where they will be scrutinised by the scientific community.

It’s not yet clear that the improvements seen in these trials could actually correlate to slowing of progression; larger and longer clinical trials would be required to demonstrate this.

A phase 2 trial of anti-LINGO-1is ongoing in relapsing remitting MS andsecondary progressive MS, and is expected to finish expected early next year.

Read more about anti-LINGO-1 and phenytoin.

Related news

MS Society talks MS SMART trial on BBC News

New research partnership to tackle degenerative conditions

MS-SMART trial for secondary progressive MS underway

Useful Links

MS Discovery Forum Multiple Sclerosis Journal Neurology Annals of Neurology Coming soon Australian and New Zealand Association of Neurologists annual meeting, 12-15 May, Auckland, New Zealand European Multiple Sclerosis Platform spring conference, 15 May, Warsaw, Poland

MS Discovery Forum Multiple Sclerosis Journal Neurology Annals of Neurology ......................................................................................................................................................................... This email was sent by: MS International Federation Skyline House, 200 Union Street, London SE1 0LX United Kingdom MS International Federation is a charity and company limited by guarantee, registered in England and Wales. Company No: 05088553. Registered Charity No: 11053. MS International Federation would like to thank Genzyme and EMD Serono for their kind support for this newsletter. MS International Federation has full editorial control of all its communications.

www.msif.org +44 (0)20 7620 1911info@msif.org

MS Topics for review

Tips to Stay Mobile When You Have MS
ARTICLE
Don’t let the condition keep you from getting around. Learn why it can help to pick the right shoes, modify your car, and even get a service dog.



8 Ways to Live Better
ARTICLE
Take control of the disease -- prepare for how it could affect your job, family, and finances.


Tips to Deal With Eye Problems
ARTICLE
What are the most common vision problems linked to multiple sclerosis? Find out.


MS or Temporal Lobe Seizures?
COMMUNITY
He’s having symptoms that mimic both conditions. Is it possible to have both at the same time? Get insights.


Can Your Diet Prevent MS?
ARTICLE
Eating healthy might not lower someone's risk of getting the disease, a study says.

Parenting ARTICLE MS can affect your approach to parenting, but that doesn’t have to be a bad thing. Top Picks • Tips to Improve Your Sex Life • How to Make Your Home MS-Friendly • Celebrities Who Live With MS MS Essentials • Do You Know the Different Types of MS? • Signs You May Be Having a Relapse Link: http://view.messages.webmd.com/

Experimental drug that may repair nerve damage in MS

Experimental drug that may repair nerve damage in MS moves forward
Last updated: Thursday 16 April 2015

Multiple Sclerosis
Neurology / Neurosciece
Adapted media release


A new study suggests that an investigational drug for multiple sclerosis (MS) may repair myelin, the fatty material that protects nerves and is damaged in MS, according to a study released April 14, 2015 that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.

"This study, for the first time, provides biological evidence of repair of damaged myelin in the human brain, and advances the field of neuro-reparative therapies," said study lead author Diego Cadavid, MD, with Biogen in Cambridge, Mass., and a Fellow with the American Academy of Neurology.

The Phase 2 study involved 82 people who had their first incident of acute optic neuritis, a disease that typically affects one eye and is characterized by inflammation, damage to the nerve fibers and loss of myelin within the optic nerve. It is estimated that about half of people with optic neuritis will later develop multiple sclerosis.

All participants were treated with high dose steroids and then randomly selected with equal probability to receive either the experimental antibody, called anti-LINGO-1, or a placebo once every four weeks, for a total of six doses. Participants were then assessed every four weeks for six months and a final visit at eight months. The drug's effectiveness in repairing myelin was evaluated by comparing the recovery of the optic nerve latency in the damaged eye at six and eight months to the normal unaffected eye at the start of the study.

The main finding of the study focused on the latency of the visual evoked potential (VEP), a test that measures the visual system's ability to conduct electrical signals between the retina and the brain. The results showed that people treated with the experimental drug and who did not miss more than one dose (per protocol population) had significantly improved conduction as measured by latency recovery compared to people who received the placebo. At six months, those who received the drug improved on average by 7.55 milliseconds, or 34 percent, compared to placebo. The effect continued to eight months with an average improvement of 9.13 milliseconds or 41 percent over placebo.

In addition, the percentage of subjects whose VEP latency in the affected eye recovered to normal or nearly normal (within 10 percent of the normal eye) more than doubled, from 26 percent on placebo to 53 percent on the drug.

A sub-study using an exploratory method of measuring latency called multifocal VEP revealed similar treatment effects.


"More studies are needed to evaluate whether these changes lead to clinical improvement," said Cadavid.

A second study of anti-LINGO-1 in people with multiple sclerosis is ongoing.



The study was supported by Biogen.

Adapted by MNT from original media release



Source:http://www.medicalnewstoday.com/releases/292447.php

Toni Bernhard In Psychology Today

Turning Straw Into Gold
Life through a Buddhist lens

Toni Bernhard, J.D., is a former law professor at University of California at Davis. She's the author of How to Be Sick, How to Wake Up, and How to Live Well with Chronic Pain and Illness

She writes about living with chronic illness in Psychology Today, as well as, having 2 books published.

Book Review

By Frederic and Mary Ann Brussat

 

How to Be Sick 

A Buddhist-Inspired Guide for the Chronically Ill and Their Caregivers 

Toni Bernhard

Wisdom Publications 09/10 Paperback 

ISBN: 9780861716265

Toni Bernhard taught at Davis School of Law at the University of California from 1982 until 2004 when she retired due to a mysterious illness which struck her while she was in Paris, France.

The symptoms were similar to those accompanying a severe flu: a dazed sick feeling, a low-grade headache, extreme fatigue, a pounding heart, and an inability to concentrate. 

This chronic debilitating disease has lasted for nine years and has been diagnosed as a variety of possible diseases from Chronic Fatigue Syndrome to Viral Induced Central Nervous System Dysfunction. 

In this down-to-earth book filled with invaluable wisdom and spiritual practices, Bernhard has found a way to make good stewardship of her disease by helping others in the same boat, along with their caregivers.

In the late 1990s, the author heard Joseph Goldstein allude to the universal law of impermanence as "Anything can happen at any time." 

For her that had come to include getting sick and not getting better. 

Then Bernhard came across "broken glass practice" by Thai Buddhist monk Ajahn Chah, referring to the uncertainty and unpredictability of life: 

A glass will break sooner or later; that is its nature. So be prepared to enjoy it in the present moment but not cling to it as something that will last forever.

Being a shut-in with little mobility makes it difficult for chronically ill individuals not to envy others who are able to attend weddings, go on vacations, or eat out regularly. 

Bernhard has dulled the edges of her envy through the practice of mudita or being able to rejoice in the happiness of others. 

She then shares her metta practice and concludes that nothing is more soothing to a sick body, a troubled mind, or a hardened heart.

Bernhard learns to be compassionate toward herself, throwing away self-recriminations for not regaining her health. 

In the process, she learns the healing powers of patient endurance. 

And when this passes and the dark cloud of fear arises, she rests in the thought:

"My heart is big enough to hold this fear." 

She practices equanimity in the face of the insensitive and hurtful comments people make about illness, in response to doctors and treatments, and when she's feeling overwhelmed by losses. 

She recommends a phrase suggested by Ajahn Chah about letting go: 

"I'm suffering because I don't want this to be happening but, like it or not, it is happening, so can I let go just a little — just a baby step?"

Other practices Bernhard suggests for the chronically ill and their caregivers are 

Byron Katie's inquiry method of four questions and a turnaround; 

Thich Nhat Hanh's healing the mind by living in the present moment;

Seung Sahn's "don't know mind" which acknowledges the mysteries inherent in sickness, pain, suffering, and healing; wise speech; and trying to find community in the midst of isolation. 

How to Be Sick is an eloquent and compelling account of Toni Bernhard's handling of a chronic illness. The depth and variety of spiritual practices offered in the book make it a major achievement.

 

 Books and Audios Recently Reviewed 

Reviews and database copyright © 1970 – 2012

by Frederic and Mary Ann Brussat

Book Review Link:

http://www.spiritualityandpractice.com/books/books.php?id=20250

Link:
https://www.psychologytoday.com/blog/turning-straw-gold

This is the kind of  drug I need because stopping the disease will leave me with accumulated damage which is extensive. 

New drug could reverse the damage of multiple sclerosis

A new experimental drug, called anti-LINGO-1, has been found to repair myelin, radically improving nerve signalling.



By Sarah Knapton, Science Editor
14 Apr 2015


A new drug could reverse the damage of multiple sclerosis, curing balance and vision problems for sufferers, researchers believe.

The disorder occurs when myelin, the fatty material which protects nerves is damaged, exposing the nerves and causing signalling problems between the brain and muscles.

One of the earliest indicators of multiple sclerosis is a condition called optic neuritis in which the retina stops sending electrical signals to the brain, causing vision loss.

But a new drug, called anti-LINGO-1, has been found to repair myelin, radically improving nerve signalling and completely restoring function in some cases.

Although the subjects tested have not been diagnosed with multiple sclerosis, more than half of people with optic neuritis go on to acquire the disorder.

Scientists say that crucially the new results prove that anti-LINGO-1 can repair myelin, and so should help people with MS.

"This study, for the first time, provides biological evidence of repair of damaged myelin in the human brain, and advances the field of neuro-reparative therapies," said study lead author Dr Diego Cadavid, of Biogen, which is based Cambridge, Massachusetts.

Around 100,000 people in Britain suffer from MS and there is currently no cure.

All patients involved in the trial were given the new drug or a placebo once every four weeks for a total of six doses.

Because optic neuritis only usually affects one eye, doctors evaluated the recovery of the optic nerve by comparing it with the normal healthy eye.

The results showed that 53 per cent of people on the drug saw their nerve signalling restored to normal or nearly normal while on average most saw signalling between the retina and the brain improve by 41 per cent.

The scientists are now following up patients to find out of the signalling improvement will restored their vision.

"More studies are needed to evaluate whether these changes lead to clinical improvement," said Cadavid.

The drug works by targeting ‘Lingo-1’ a protein which stops nerve cells from developing further once the nervous system is fully formed.

By blocking that protein, the drug effectively tells the body to carry on growing the nerves, which repairs any damage.

Biogen chief medical officer Alfred Sandrock said “We believe the results are encouraging, as this is the first clinical trial to provide evidence of biological repair in the central nervous system by facilitating remyelination following an acute inflammatory injury”.

The research was presented at the American Academy of Neurology's Annual Meeting in Washington.




Source: http://www.telegraph.co.uk/news/science/science-news/11535380/New-drug-could-reverse-the-damage-of-multiple-sclerosis.html

More articles:

‘Miracle’ stem cell therapy reverses multiple sclerosis

Thousands of people wrongly diagnosed with Multiple Sclerosis, experts warn

Multiple sclerosis: the facts and fictions